1) The document discusses Ophthotech's development of new therapies for age-related macular degeneration (AMD), including their lead drug Fovista. 2) Fovista is currently in Phase 3 clinical trials in combination with anti-VEGF drugs to treat wet AMD, with initial data expected in 4Q 2016. 3) Previous Phase 2b results showed Fovista in combination with Lucentis was statistically superior to Lucentis alone and had a favorable safety profile.

1. David R. Guyer, M.D.
Chief Executive Officer and Chairman of the Board
Samir Patel, M.D.
President and Vice Chairman
Developing the Next Generation of Science-driven AMD Therapies
November 2015NASDAQ: OPHT

2. Forward-Looking Statements
2
Any statements in this press release about Ophthotech’s future expectations, plans and prospects
constitute forward-looking statements for purposes of the safe harbor provisions under the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about
Ophthotech’s strategy, future operations and future expectations and plans and prospects for
Ophthotech, and any other statements containing the words “anticipate,” “believe,” “estimate,”
“expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,”
“could,” “should,” “continue,” and similar expressions. In this press release, Ophthotech’s forward
looking statements include statements about the potential receipt of milestone payments and royalties
under its ex-US licensing and commercialization agreement, the conduct of the Fovista®
Phase 3
clinical program, including obtaining initial, top-line data from the Fovista®
Phase 3 clinical program and
seeking marketing approval for Fovista®
, the potential of Fovista®
as a wet AMD combination therapy,
the initiation of additional clinical trials for Fovista®
and Zimura™, obtaining data from these additional
planned trials, Ophthotech’s strategy for the development of, and the potential therapeutic benefit of,
tivozanib for the treatment of non-oncologic conditions of the eye, including wet AMD and the potential
for related value creation for Ophthotech’s stockholders. Such forward-looking statements involve
substantial risks and uncertainties that could cause Ophthotech’s clinical development programs, future
results, performance or achievements to differ significantly from those expressed or implied by the
forward-looking statements. Such risks and uncertainties include, among others, those related to the
initiation and conduct of clinical trials, availability of data from clinical trials and expectations for
regulatory approvals or other actions and other factors discussed in the “Risk Factors” section
contained in the quarterly and annual reports that Ophthotech files with the SEC. Any forward-looking
statements represent Ophthotech’s views only as of the date of this press release. Ophthotech
anticipates that subsequent events and developments will cause its views to change. While
Ophthotech may elect to update these forward-looking statements at some point in the future,
Ophthotech specifically disclaims any obligation to do so except as required by law.
®

3. 3
Fovista®
First-in-class anti-PDGF agent for wet AMD combination
therapy; multi-billion dollar market
• Phase 3 program
• On-track; Two Phase 3 trials fully recruited; Initial, top-line data
expected in 4Q 2016
• OPHT to independently commercialize Fovista in the US; ex-US
partnership with Novartis
• Demonstrated statistically significant superiority in a large (N=449)
randomized, controlled, Phase 2b trial
• 62% comparative benefit from baseline over Lucentis® monotherapy
• No imbalances in safety profile
: Developing the Next Generation of
Science-driven AMD Therapies

4. 4
• Expanding the Pipeline
• Additional Fovista trials initiated and/or planned to address
other unmet needs for wet AMD
• Zimura® (C5 complement inhibitor) trials
• Phase 2/3: monotherapy for Geographic Atrophy (a form of dry
AMD); no approved therapy, multi-billion dollar market
opportunity (to initiate shortly)
• Phase 2: wet AMD (PCV*) (on-going)
• Management team with successful track record in the
development and commercialization of ophthalmology
products
: Developing the Next Generation of
Science-driven AMD Therapies
*Polypoidal Choroidal Vasculopathy

5. Current Anti-VEGF Market:
Expanding Multi-Billion Dollar Opportunity
5
Lucentis®
**Eylea®
Sales in First 12 Months Following Launch
**Available sales data is for 13 months 10 days following launch
$800MM
$862MM
*Ophthotech internal estimate
Annual Global Branded Anti-VEGF Sales*($Bn)
0.4
1.2
1.8
2.3
2.9
3.8
4.8
0.0
1.0
2.0
3.0
4.0
5.0
6.0
7.0
6.1
7.1
2006 2007 2008 2009 2010 2011 2012 2013 2014

6. 6
Severity of AMD
Mild (20/40)
Moderate (20/80)
Severe (20/200)
Extreme (CF)
No light
Comparable
Minor stroke
Angina upon exertion
Breast Ca on chemo
Renal Disease s/p transplant
Bilateral Osteoarthritis of hip
Complete Incontinence
End stage renal disease on dialysis
Ulcerative colitis requiring surgery
Cardiac cripple
Impact of AMD (Value-based Medicine)
Slide Courtesy of Karim Jamal, MD, Retinal Consultants of Arizona

7. VA
Letters
Lost
Monotherapy Anti-VEGF: Visual Outcome (Onset to 7 Years)
Significant Unmet Medical Need
7
Vision: Pre-Wet AMD Diagnosis
At Presentation
0
-7
-15
-3
2- 3 Years
• Majority do not gain significant vision
• ~20-30% lose additional vision
After 4-7 Years
• No improvement in vision compared to
acute visual loss at presentation
UNMET MEDICAL NEED
PERSISTENT VISUAL LOSS
Ophthalmology 2013; 120-2292-2299

8. Fovista Phase 3 Program in Wet AMD
8
Fovista 1.5mg + Lucentis Consistent w/Lucentis dosing schedule
Q4W approved in EU*
Lucentis 0.5mg Consistent w/Lucentis dosing schedule
Q4W approved in EU*
Trial 1
Enrollment
Completed
Year 1
Fovista 1.5mg + Lucentis Q8W (pre-specified PRN therapy during
Q4W non-treating months)
Lucentis 0.5mg Q8W (pre-specified PRN therapy during
Q4W non-treating months)
Fovista 1.5mg + Avastin 1.25mg /Eylea 2mg Avastin: Q4W / Eylea: Q8W
Avastin Q4W / Eylea Q4W for 3 months, then Q8W
Avastin 1.25mg / Eylea 2mg Avastin Q4W / Eylea Q8W
Avastin Q4W / Eylea Q4W for 3 months, then Q8W
Primary Endpoint: Mean Change in Visual Acuity from Baseline at 1-Year
PrimaryEndpoint–1-Year
Year 2
Trial 3
*Approved 2013 label
OPHT expects to enroll a total of approximately 1,866 patients in the three trials
Trial 2
Enrollment
Completed

9. • Recruitment completed in both Fovista in combination with
Lucentis trials
• Fovista in combination with either Eylea or Avastin
continues to enroll patients on track
• Regulatory strategy: make Fovista available to patients as
quickly as possible*
• Initially submit a New Drug Application to the FDA for Fovista in
combination with Lucentis
• Subsequently submit an amendment to the NDA with data from the Fovista in
combination with Eylea or Avastin trial; or
• File a supplemental NDA for Fovista in combination with Eylea or Avastin
following FDA review of the NDA for Fovista in combination with Lucentis
9
Fovista Phase 3 Program in Wet AMD
Initial, Topline Data Expected in 4Q 2016
*assumes a positive outcome for the Fovista Phase 3 program in wet AMD and marketing approval is granted

10. Fovista Phase 2b: Early and Sustained Improvement Over Time
10
0
3
6
9
12
wk 0 wk 4 wk 8 wk 12 wk 16 wk 20 wk 24
MeanChangeVA(Letters)
Fovista 1.5mg
(Anti-PDGF) + Lucentis®
Fovista 0.3mg
(Anti-PDGF) + Lucentis®
Lucentis
0.5mg Lucentis 0.3mg Fovista + Lucentis 1.5mg Fovista + Lucentis
Intent to Treat population using Last Observation Carried Forward (ITT LOCF)
Classic dose response curve

11. Fovista Phase 2b: No Imbalances in Safety Profile
11
# of Patients (%)
Monotherapy
Lucentis®
N = 148
0.3mg Fovista
+ Lucentis®
N = 149
1.5mg Fovista
+ Lucentis®
N = 152
Ocular Serious Adverse Events – Eye
Disorders
1 (0.7%) 1 (0.7%) 1 (0.7%)
Corneal Erosion 0 (0.0%) 0 (0.0%) 1 (0.7%)
Uveitis 0 (0.0%) 1 (0.7%) 0 (0.0%)
Visual Acuity Reduced 1 (0.7%) 0 (0.0%) 0 (0.0%)
Patients With ≥ 1 Systemic SAE 11 (7.4%) 13 (8.7%) 9 (5.9%)
MedDRA System Organ Class (1)
Cardiac Disorders 2 (1.4%) 2 (1.3%) 2 (1.3%)
Gastrointestinal Disorders 1 (0.7%) 2 (1.3%) 3 (2.0%)
Infections 1 (0.7%) 2 (1.3%) 0 (0.0%)
Musculoskeletal Disorders 1 (0.7%) 0 (0.0%) 2 (1.3%)
Neoplasms 3 (2.0%) 3 (2.0%) 1 (0.7%)
Nervous System Disorders 3 (2.0%) 1 (0.7%) 0 (0.0%)
Respiratory Disorders 0 (0.0%) 3 (2.0%) 2 (1.3%)
Any APTC Event(2) 3 (2.0%) 1 (0.7%) 0 (0.0%)
Non-Fatal Myocardial Infarction 0 (0.0%) 0 (0.0%) 0 (0.0%)
Non-Fatal Stroke 2 (1.4%) 1 (0.7%) 0 (0.0%)
Vascular Death 1 (0.7%) 0 (0.0%) 0 (0.0%)
Note
1. Data are listed only for system organ classes with 3 or more events.
2. Antiplatelet Trialists’ Collaboration
3. Table omits patients with one or more systemic adverse events

12. Subretinal Fibrosis is the End Stage of Wet AMD
• Urgent, unmet medical need -
prevention of fibrosis in wet
AMD
• Fibrotic scarring of the retina
is observed in up to 45% of
patients on monotherapy
Lucentis® by 2 years*
• Fibrotic scarring - biomarker
for predicting poor final visual
acuity
12
*Daniel, E., et al. Comparison of Age-related Macular Degeneration Treatments Trials Research, G. (2013). Risk of Scar in the Comparison of Age-related Macular Degeneration
Treatments Trials. Ophthalmology.
*Bloch, S. B., et al. (2013). Subfoveal fibrosis in eyes with neovascular age-related macular degeneration treated with intravitreal ranibizumab. Am J Ophthalmol, 156(1), 116-124
e111

13. Anti-PDGF Therapy as an Anti-Fibrotic Agent
• PDGF is a mediator of fibrosis in multiple pre-
clinical models of organ fibrosis and retinal scarring
• Fovista monotherapy was shown to be anti-fibrotic
in a preclinical model of retinal scarring and
fibrosis
 Akiyama et al., (2006) Intraocular injection of an aptamer that binds PDGF-B: a
potential treatment for proliferative retinopathies: J Cell Physiol. May;207(2):407-12
13

14. BASELINE WK 24
Lucentis Monotherapy
BASELINE WK 24
Fovista + Lucentis Combination

15. AAO Abstract*
Masked retrospective analysis by independent reading center of fundus
images at baseline and 24 weeks in a subset (70 eyes) from the Fovista
Phase 2b study with >0 ETDRS letter loss.
• Mean change in fibrosis: 0.97 vs. 2.0 (P = 0.003)
• 27% of eyes (Fovista + Lucentis) vs. 54%
(Lucentis monotherapy) had ≥ 2 step worsening
of fibrosis (2x difference)
• In eyes with no fibrosis, 10% (Fovista + Lucentis)
vs. 51% (Lucentis monotherapy) developed
fibrosis
15
* Chakravarthy U, Jaffe GJ, Dual Antagonism of Platelet Derived Growth Factor (Fovista 1.5mg) and Vascular Endothelial Growth Factor (Lucentis 0.5mg) Results in Reduced Sub-retinal
Fibrosis and Neovascular Growth. Paper presentation at the 2014 American Academy of Ophthalmology Annual Meeting, October 21, 2014. Abstract PA092.

16. Subfoveal Fibrosis Develops at ~ 3 to 6 months
Following Initiation of Anti-VEGF Therapy
16
Kaplan-Meier fibrosis-specific curves
Bloch SB et al. Am J Ophthalmol 2013;156:116–124
All Forms of Subfoveal Fibrosis Subfoveal Fibrosis with Retinal Atrophy
Neovascular AMD

17. Ophthotech’s Ex-US Fovista Deal with Novartis
One of the Largest Single Product Partnering Deals
• Deal totals over $1 billion in upfront and potential milestone
payments
• Immediate payment and near-term milestones totaling $330 million
• Received upfront fee of $200 million
• Phase 3 enrollment-based milestones of $130 million
• Achieved $50 million milestone in Q3 ’14 and $50 million milestone in 1Q ‘15
• Eligible for contingent future milestones totaling up to $700 million
• Marketing approval milestones of $300 million
• Sales milestones of $400 million
• A mid-30 percent range royalty on ex- US net sales of Fovista as a
stand alone product
• Approximately equal value on ex-US co-formulated Fovista products
• Ophthotech remains responsible for existing royalties owed to third parties
17

18. Fovista: Licensing and Commercialization Strategy
Phase 3 Program Remains Unchanged
• Fovista Phase 3 program
• Ophthotech continues to lead global clinical program
• US registration managed by OPHT; collaborate on ex-US regulatory with NVS
• Fovista development strategy remains anti-VEGF agnostic
• Separate injections provide choice of preferred anti-VEGF agent in
combination with Fovista
• Delivery treatment alternatives; flexibility for physicians
• Novartis seeks co-formulation of Fovista with a NVS proprietary anti-VEGF
and pre-filled syringe for Fovista
• OPHT granted options to US rights
18

19. Fovista Expansion AMD Trials
• Anti-fibrosis
• Reduction of Treatment Burden
• Anti-VEGF Treatment Failures (non-responders)
19

20. Fovista IST – Dr. Pravin Dugel and Associates
• Anti-fibrosis IST
• 27 patients
• Average of ~ 25 prior anti-VEGF injections
• Persistent or recurrent fluid (treatment resistance
and/or failure)
• Duration of IST is 24 months
20
ARVO 2015 (Denver): Fovista IST Interim
Analysis at 7 months

21. 21
Short-Term Interim Analysis
Visual Acuity Outcome
Change in VA (Letters) at 7 mo..
Anti-PDGF / Anti-VEGF Combination Therapy
N=27
Treatment
Resistant
WITH
“Anti-PDGF Pre-Treatment
N=10
WITHOUT
“Anti-PDGF Pre-Treatment
N=17
ARVO 2015 (Denver): Fovista IST Interim Analysis at 7 months
+8.9 Letters
+4.4 Letters
+16.5 Letters
Pravin U. Dugel, MD presented:
- 7mo. data at The Association for Research in Vision and Ophthalmology 2015 Annual Meeting: May 2015

22. Tivozanib for Maintenance (Chronic) Phase of
Wet AMD – An Unmet Medical Need
• The unmet needs in wet AMD include treatment burden
and disappointing long-term visual outcome in the chronic
phase of wet AMD therapies
• Focus initially on a sustained release formulation as a
treatment for the chronic phase of wet AMD therapy
• Highly potent, selective small molecule VEGF tyrosine kinase
inhibitor with ideal properties for the development of a SR
formulation
• Fovista’s development strategy remains agnostic for the
initial acute phase of anti-VEGF therapy for wet AMD
22

23. Ophthotech’s Anti-Complement Dry AMD (GA)
Program
• OPHT’s Zimura hits C5 pathway
• Phase 2a trial with Zimura monotherapy completed
• Recent third party data supports complement
inhibition as a target in dry AMD (GA)
• Phase 2/3 to initiate shortly
• All worldwide commercialization rights retained for
Zimura
23

24. Financial Overview
• Cash Resources
– $426M cash, cash equivalents and marketable securities as of
September 30, 2015
• $125M royalty purchase financing led by Novo A/S
• Entered into May 2013 ($41.7M)
• Achieved enrollment milestones in January 2014 ($41.7M) and November 2014
($41.7M)
• Completed $192 Million IPO in September 2013
• Completed $59.9M follow-on public offering in February 2014
– Ex-US licensing and commercialization agreement with Novartis in May
2014
• Over $1 Billion, inclusive of upfront fee and potential milestone payments
• Immediate payment and near-term milestone totaling up to $330M
• Received an upfront fee of $200M
• Enrollment-based milestones of up to $130M ($50M achieved in September
2014 and $50M achieved in March 2015)
24

25. 25
Fovista®
First-in-class anti-PDGF agent for wet AMD combination
therapy; multi-billion dollar market
• Phase 3 program
• On-track; Two Phase 3 trials fully recruited; Initial, top-line data
expected in 4Q 2016
• OPHT to independently commercialize Fovista in the US; ex-US
partnership with Novartis
• Demonstrated statistically significant superiority in a large (N=449)
randomized, controlled, Phase 2b trial
• 62% comparative benefit from baseline over Lucentis® monotherapy
• No imbalances in safety profile
: Developing the Next Generation of
Science-driven AMD Therapies

26. 26
• Expanding the Pipeline
• Additional Fovista trials initiated and/or planned to address
other unmet needs for wet AMD
• Zimura® (C5 complement inhibitor) trials
• Phase 2/3: monotherapy for Geographic Atrophy (a form of dry
AMD); no approved therapy, multi-billion dollar market
opportunity (to initiate shortly)
• Phase 2: wet AMD (PCV*) (on-going)
• Management team with successful track record in the
development and commercialization of ophthalmology
products
: Developing the Next Generation of
Science-driven AMD Therapies
*Polypoidal Choroidal Vasculopathy

27. 27
~ R&D INVESTOR DAY ~
Join Ophthotech Alongside an Elite Panel of
Retinal Specialists
for its R&D Investor Day
THURSDAY, DECEMBER 3, 2015
7:45am – 11:15am
New York, NY
Contact Kathy Galante (kathy.galante@ophthotech.com) to register